Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | NR4A2 | P43354 | 7/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.45 |
| ▸ | NR1H4 | Q96RI1 | 4/20 | 0.44 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.44 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5720725 | 0.89 | KMT2A (0.42) | KMT2APOLBNPC1RAB9AMEN1 | |
| SCHEMBL1122939 | 0.86 | KMT2A (0.45) | KMT2APOLBNPC1RAB9AMEN1 | |
| SCHEMBL1123197 | 0.81 | MEN1 (0.43) | KMT2APOLBNR1H4NPC1RAB9A | |
| SCHEMBL1122848 | 0.78 | LMNA (0.46) | KMT2APOLBNPC1RAB9AMEN1 | |
| SCHEMBL1122685 | 0.77 | F10 (0.38) | KMT2AMEN1 | |
| SCHEMBL9803295 | 0.77 | KMT2A (0.80) | KMT2ANR4A2POLBPLA2G4BNR1H4 | |
| SCHEMBL10787479 | 0.77 | KMT2A (0.80) | KMT2ANR4A2POLBPLA2G4BNR1H4 | |
| SCHEMBL30167982 | 0.77 | KMT2A (0.80) | KMT2ANR4A2POLBPLA2G4BNR1H4 | |
| SCHEMBL4509654 | 0.75 | KMT2A (0.77) | KMT2ANR4A2PLA2G4BNR1H4AKR1C3 | |
| SCHEMBL21119057 | 0.74 | ACMSD (0.55) | NPC1RAB9AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1644321-B1 | NEW BENZAMIDES AS PPATY MODULATORS | S A L V A T LAB SA (ES) | 2011-02-09 | — | — | EP | disclosed |
| US-20060160894-A1 | Benzamides as ppar modulators | LABORATORIOS S.A.L.V.A.T.,S.A. (ES) | 2006-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060160894-A1 | Benzamides as ppar modulators | PPARD, PPARA, PPARG | KMT2A 1515/4885NR4A2 66/4885POLB 791/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.